Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: A systematic review and meta-analysis

Drug Design, Development and Therapy

Volumn 9, Issue , 2015, Pages 5397-5405

  Ba, Jun ^a,b   Peng, Run Sheng ^b   Xu, Ding ^a   Li, Yan Hong ^a   Shi, Hui ^a,c   Wang, Qianyi ^a   Yu, Jing ^a  

^a TONGJI UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Aflibercept; Age related macular degeneration; Bevacizumab; Meta analysis; Ranibizumab; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PHOTOSENSITIZING AGENT; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; CATARACT; DRUG EFFICACY; DRUG FATALITY; ENDOPHTHALMITIS; HUMAN; HYPERTENSION; META ANALYSIS; PHOTODYNAMIC THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA HEMORRHAGE; RETINAL THICKNESS; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VISUAL ACUITY; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; MULTIMODALITY CANCER THERAPY; ODDS RATIO; PATHOLOGY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; RETINA; SIGNAL TRANSDUCTION; SUBRETINAL NEOVASCULARIZATION; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANIMALS; BEVACIZUMAB; CHOROIDAL NEOVASCULARIZATION; COMBINED MODALITY THERAPY; HUMANS; INTRAVITREAL INJECTIONS; ODDS RATIO; PHOTOCHEMOTHERAPY; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINA; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84943164078     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S86269     Document Type: Review

References (38)

1. Pascolini D, Mariotti SP, Pokharel GP, et al. 2002 Global update of available data on visual impairment: a compilation of population-based prevalence studies. Ophthalmic Epidemiol. 2004;11(2):67-115.
2. Friedman DS, O’Colmain BJ, Mufioz B, et al. Eye Diseases Prevalence Research Group: prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122(4):564-572.
3. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians-a systematic review and meta-analysis. Ophthalmology. 2010;117(5):921-927.
4. Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration-a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(1):116-126.
5. Thomas M, Mousa SS, Mousa SA. Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration. Clin Ophthalmol. 2013;7:495-501.
6. Emerson MV, Lauer AK. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008;2(2):377-388.
7. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
8. Cruess AF, Berger A, Colleaux K, et al. Canadian expert consensus: optimal treatment of neovascular age-related macular degeneration. Can J Ophthalmol. 2012;47(3):227-235.
9. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012;154(2):222-226.
10. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trial. 1996;17(1):1-12.
11. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus Bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority ranibizumab trial. Ophthalmology. 2013;120(11):2300-2309.
12. Krebs I, Vecsei Marlovits V, Bodenstorfer J, et al. Comparison of Ranibizumab monotherapy versus combination of Ranibizumab with photodynamic therapy with neovascular age-related macular degeneration. Acta Ophthalmologica. 2013;91(3):e178-e183.
13. Larsen M, Schmidt-Erfurth U, Lanzetta P, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results. Ophthalmology. 2012;119(5):992-1000.
14. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119(7):1399-1411.
15. Subramanian ML, Abedi G, Ness S, et al. Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial. Eye (Lond). 2010;24(11):1708-1715.
16. Vallance JH, Johnson B, Majid MA, Banerjee S, Mandal K, Bailey CC. A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond). 2010;24(10):1561-1567.
17. Busbee BG, Ho AC, Brown DM, et al; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-1056.
18. Martin DF, Maguire MG, Fine SL, et al; Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
19. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Ophthalmology. 2012;119(5):1001-1010.
20. Williams PD, Callanan D, Solley W, Avery RL, Piramici DJ, Aaberg T. A prospective pilot study comparing combined intravitreal ranibizumab and half-influence photodynamic therapy with ranibizumab in the treatment of neovascular age-related macular degeneration. Clin Ophthalmol. 2012;6:1529-1525.
21. Heier JS, Brown DM, Chong V, et al; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537-2548.
22. Krebs I, Schmetterer L, Boltz A, et al; MANTA Research Group. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97(3):266-271.
23. Spaide RF, Laud K, Fine HF, et al. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina. 2006;26(4):383-390.
24. Bashshur ZF, Haddad ZA, Schakal A, Jaafar RF, Saab M, Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a one-year prospective study. Am J Ophthalmol. 2008;145(2):249-256.
25. Sacu S, Michels S, Prager F, et al. Randomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term results. Eye (Lond). 2009;23(12):2223-2227.
26. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina. 2006;26(5):495-511.
27. Tufail A, Patel PJ, Egan C, et al. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010;340:c2459.
28. Bashshur ZF, Schakal A, Hamam RN, El Haibi CP, Jaafar RF, Noureddin BN. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration. Arch Ophthalmol. 2009;125(10):1357-1361.
29. Ghazi NG, Knape RM, Kirk TQ, Tiedeman JS, Conway BP. Intravitreal bevacizumab (avastin) treatment of retinal angiomatous proliferation. Retina. 2008;28(5):689-695.
30. Goff MJ, Johnson RN, McDonald HR, Ai E, Jumper JM, Fu A. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Retina. 2007;27(4):432-438.
31. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
32. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65.
33. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114(10):1868-1875.
34. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol. 2010;94(1):2-13.
35. Zhang XY, Guo XF, Zhang SD, et al. Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. Int J Ophthalmol. 2014;7(2):355-364.
36. Solom SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8:CD005139.
37. Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:1175-1186.
38. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six week results of the VIEW studies. Ophthalmology. 2014; 121(1):193-201.